The cost-utility of sequential adjuvant trastuzumab in women with Her2/Neu-Positive Breast Cancer: An analysis based on updated results from the HERA trial

科研成果: 期刊稿件文章同行评审

32 引用 (Scopus)
源语言英语
页(从-至)641-648
页数8
期刊Value in Health
12
5
DOI
出版状态已出版 - 2009

!!!ASJC Scopus Subject Areas

  • 公共卫生、环境和职业健康
  • 卫生政策

指纹

探究 'The cost-utility of sequential adjuvant trastuzumab in women with Her2/Neu-Positive Breast Cancer: An analysis based on updated results from the HERA trial' 的科研主题。它们共同构成独一无二的指纹。

引用此

Skedgel, C., Rayson, D., & Younis, T. (2009). The cost-utility of sequential adjuvant trastuzumab in women with Her2/Neu-Positive Breast Cancer: An analysis based on updated results from the HERA trial. Value in Health, 12(5), 641-648. https://doi.org/10.1111/j.1524-4733.2009.00511.x